Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands.
Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, The Netherlands.
Theranostics. 2020 Apr 6;10(12):5357-5367. doi: 10.7150/thno.42224. eCollection 2020.
Fluorescence molecular endoscopy (FME) is an emerging technique in the field of gastroenterology that holds potential to improve diagnosis and guide therapy, by serving as a 'red-flag' endoscopic imaging technique. Here, we investigated the safety, feasibility and optimal method of administration of EMI-137, targeting c-Met, during FME in Barrett's Esophagus (BE) and report several outcome parameters for early phase FME studies. : FME was performed in 15 Barrett's neoplasia patients. EMI-137 was administered to three cohorts of five patients: 0.13 mg/kg intravenously (IV); 0.09 mg/kg IV or topically at a dose of 200 μg/cm BE (n=1) or 100 μg/cm BE (n=4). Fluorescence was visualized quantified using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy and correlated to histopathology and immunohistochemistry. EMI-137 localization was assessed using fluorescence microscopy. : FME using different IV and topical doses of EMI-137 appeared to be safe and correctly identified 16/18 lesions, although modest target-to-background ratios were observed (median range of 1.12-1.50). C-Met overexpression varied between lesions, while physiological expression in the stomach-type epithelium was observed. Microscopically, EMI-137 accumulated around the neoplastic cell membranes. We identified several outcome parameters important for the validation of EMI-137 for FME: 1) the optimal administration route; 2) optimal dose and safety; 3) FME contrast; 4) quantification of intrinsic fluorescence; 5) correlation of fluorescence, histopathology and target expression; and 6) microscopic tracer distribution. : C-Met targeted FME using EMI-137 may not be the ideal combination to improve BE surveillance endoscopies, however the identified outcome parameters may serve as a valuable guidance for designing and performing future early phase clinical FME studies, independent of which fluorescent tracer is investigated.
荧光分子内镜(FME)是消化内镜领域的一项新兴技术,具有改善诊断和指导治疗的潜力,可作为一种“红旗”内镜成像技术。在这里,我们研究了在 Barrett 食管(BE)中使用针对 c-Met 的 EMI-137 进行 FME 的安全性、可行性和最佳给药方法,并报告了几项早期 FME 研究的结果参数。 FME 对 15 例 Barrett 肿瘤患者进行了检查。将 EMI-137 给予三组五名患者:静脉内 0.13 mg/kg(IV);0.09 mg/kg IV 或 200μg/cm BE 剂量(n=1)或 100μg/cm BE 剂量(n=4)局部给药。使用多直径单纤维反射率、单纤维荧光(MDSFR/SFF)光谱对荧光进行可视化和量化,并与组织病理学和免疫组织化学相关联。使用荧光显微镜评估 EMI-137 定位。 使用不同的 IV 和局部 EMI-137 剂量进行 FME 似乎是安全的,能够正确识别 16/18 个病变,尽管观察到适度的靶标与背景的比值(中位数范围为 1.12-1.50)。C-Met 过表达在病变之间存在差异,而胃型上皮的生理表达则观察到。显微镜下,EMI-137 积聚在肿瘤细胞膜周围。我们确定了几个对于 EMI-137 用于 FME 的验证非常重要的结果参数:1)最佳给药途径;2)最佳剂量和安全性;3)FME 对比;4)固有荧光的量化;5)荧光、组织病理学和靶标表达的相关性;6)显微镜示踪剂分布。 使用 EMI-137 进行 C-Met 靶向 FME 可能不是改善 BE 监测内镜的理想组合,但是确定的结果参数可能作为设计和进行未来早期 FME 临床研究的有价值的指导,而与研究哪种荧光示踪剂无关。